SEARCH

SEARCH BY CITATION

References

  • Acikgoz O., Gonenc S., Kayatekin B. M., Uysal N., Pekcetin C., Semin I., Gure A. (1998) Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum. Brain Res. 813, 200202.
  • Albers D. S. & Sonsalla P. K. (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther. 275, 11041114.
  • Berman S. B. & Hastings T. G. (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73, 11271137.
  • Bowyer J. F., Clausing P., Schmued L., Davies D. L., Binienda Z., Newport G. D., Scallet A. C., Slikker W. Jr (1996) Parenterally administered 3-nitropropionic acid and amphetamine can combine to produce damage to terminals and cell bodies in the striatum. Brain Res. 712, 221229.
  • Burrows K. B., Gudelsky G., Yamamoto B. K. (2000a) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur J. Pharmacol. 398, 1118.
  • Burrows K. B., Nixdorf W. L., Yamamoto B. K. (2000b) Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines. J. Pharmacol. Exp. Ther. 292, 853860.
  • Cadet J. L. & Brannock C. (1998) Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. 32, 117131.
  • Cadet J. L., Sheng P., Ali S., Rothman R., Carlson E., Epstein C. (1994) Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 62, 380383.
  • Cappon G. D., Broening H. W., Pu C., Morford L., Vorhees C. V. (1996) alpha-Phenyl-N-tert-butyl nitrone attenuates methamphetamine-induced depletion of striatal dopamine without altering hyperthermia. Synapse 24, 173181.
  • Chan P., Di Monte D. A., Luo J. J., DeLanney L. E., Irwin I., Langston J. W. (1994) Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem. 62, 24842487.
  • De Vito M. J. & Wagner G. C. (1989) Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 28, 11451150.
  • Deng X., Ladenheim B., Tsao L. I., Cadet J. L. (1999) Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J. Neurosci. 19, 1010710115.
  • Eisch A. J. & Marshall J. F. (1998) Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse 30, 433445.
  • Esterbauer H., Schaur R. J., Zollner H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11, 81128.
  • Fleckenstein A. E., Wilkins D. G., Gibb J. W., Hanson G. R. (1997) Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J. Pharmacol. Exp. Ther. 283, 281285.
  • Giovanni A., Liang L. P., Hastings T. G., Zigmond M. J. (1995) Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 64, 18191825.
  • Gluck M. R., Jayatilleke E., Shaw S., Rowan A. J., Haroutunian V. (2000) CNS oxidative stress associated with the kainic acid rodent model of experimental epilepsy. Epilepsy Res. 39, 6371.
  • Graham D. G., Tiffany S. M., Bell W. R. J., Gutknecht W. F. (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644653.
  • Harold C., Wallace T., Friedman R., Gudelsky G., Yamamoto B. (2000) Methamphetamine selectively alters brain glutathione. Eur. J. Pharmacol. 400, 99102.
  • Hirata H., Ladenheim B., Carlson E., Epstein C., Cadet J. L. (1996) Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res. 714, 95103.
  • Hirata H., Asanuma M., Cadet J. L. (1998) Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain. Synapse 30, 150155.
  • Hogan K. A., Staal R. G. W., Sonsalla P. K. (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: Disparity between homogenates and vesicle preparations. J. Neurochem. 74, 22172220.
  • Imam S. Z., Crow J. P., Newport G. D., Islam F., Slikker W. J., Ali S. F. (1999) Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: protective effects of peroxynitrite decomposition catalyst. Brain Res. 837, 1521.
  • Imam S. Z., Newport G. D., Itzhak Y., Cadet J. L., Islam F., Slikker W. J., Ali S. F. (2001) Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J. Neurochem. 76, 745749.
  • Kita T., Takahashi M., Kubo K., Wagner G. C., Nakashima T. (1999) Hydroxyl radical formation following methamphetamine administration to rats. Pharmacol. Toxicol. 85, 133137.
  • Kita T., Shimada K., Mastunari Y., Wagner G. C., Kubo K., Nakashima T. (2000) Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology 39, 399406.
  • Kuhn D. M. & Geddes T. J. (2000) Molecular footprints of neurotoxic amphetamine action. Ann. NY Acad. Sci. 914, 92103.
  • LaVoie M. J. & Hastings T. G. (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19, 14841491.
  • Levine R. L., Garland D., Oliver C. N., Amici A., Climent I., Lenz A. G., Ahn B. W., Shaltiel S., Stadtman E. R. (1990) Determination of carbonyl content in oxidatively modified proteins. Meth. Enzymol. 186, 464478.
  • Li H. & Dryhurst G. (1997) Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J. Neurochem. 69, 15301541.
  • Lotharius J. & O'Malley K. L. (2000) The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275, 3858138588.
  • Lowry O. H., Rosenbrough N. J., Farr A. L., Randall R. J. (1951) Protein measurement with folin reagent. J. Biol. Chem. 193, 265272.
  • McCann U. D., Wong D. F., Yokoi F., Villemagne V., Dannals R. F., Ricaurte G. A. (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci. 18, 84178422.
  • Nakamura K., Bindokas V. P., Marks J. D., Wright D. A., Frim D. M., Miller R. J., Kang U. J. (2000) The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol. Pharmacol. 58, 271278.
  • O'Callaghan J. P. & Miller D. B. (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 741751.
  • Ohmori T., Koyama T., Muraki A., Yamashita I. (1993) Competitive and noncompetitive N-methyl-d-aspartate antagonists protect dopaminergic and serotonergic neurotoxicity produced by methamphetamine in various brain regions. J. Neural Transmission – General Section 92, 97106.
  • Rice-Evans C. A., Diplock A. T., Symons M. C. R. (1991) Mechanisms of Radical Production. In: Laboratory Techniques in Biochemistry and Molecular Biology: Techniques in Free Radical Research (Burdon, R. H. and Van Knippenberg, P. H., eds), pp. 1950. Elsevier, New York.
  • Schmued L. C. & Bowyer J. F. (1997) Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Res. 759, 135140.
  • Seiden L. S., Sabol K. E., Ricaurte G. A. (1993) Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33, 639677.
  • Sonsalla P. K., Nicklas W. J., Heikkila R. E. (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243, 398400.
  • Sonsalla P. K., Riordan D. E., Heikkila R. E. (1991) Competitive and noncompetitive antagonists at N-methyl-d-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther. 256, 506512.
  • Sonsalla P. K., Jochnowitz N. D., Zeevalk G. D., Oostveen J. A., Hall E. D. (1996) Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 738, 172175.
  • Stumm G., Schlegel J., Schafer T., Wurz C., Mennel H. D., Krieg J. C., Vedder H. (1999) Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J. 13, 10651072.
  • Sulzer D., Chen T. K., Lau Y. Y., Kristensen H., Rayport S., Ewing A. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 41024108.
  • Volkow N. D., Chang L., Wang G. J., Fowler J. S., Leonido-Yee M., Franceschi D., Sedler M. J., Gatley S. J., Hitzemann R., Ding Y. S., Logan J., Wong C., Miller E. N. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 158, 377382.
  • Wan F. J., Lin H. C., Huang K. L., Tseng C. J., Wong C. S. (2000) Systemic administration of d-amphetamine induces long-lasting oxidative stress in the rat striatum. Life Sci. 66, L205L212.
  • Wilson J. M., Kalasinsky K. S., Levey A. I., Bergeron C., Reiber G., Anthony R. M., Schmunk G. A., Shannak K., Haycock J. W., Kish S. J. (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2, 699703.
  • Wrona M. Z. & Dryhurst G. (1998) Oxidation of serotonin by superoxide radical: implications to neurodegenerative brain disorders. Chem. Res. Toxicol. 11, 639650.
  • Yamamoto B. K. & Zhu W. (1998) The effects of methamphetamine on the production of free radicals and oxidative stress. J. Pharmacol. Exp. Ther. 287, 107114.